The lifetime risk for a hip fracture in Swedish women and men is 23% and 11%, respectively; dementia doubles this risk, said Prof. Dorota Religa (Karolinska Institutet, Sweden) [1]. Hip fractures are a major cause of morbidity and mortality among the elderly. Dementia is common in this population and complicates recovery from hip fracture surgery, which is the only treatment option. Previous studies have suggested an increased mortality risk in hip fracture patients with dementia, but had several limitations, such as small sample sizes and limited data on dementia subtypes. To gain insight into the exact association between dementia and mortality after hip fracture surgery, Prof. Religa and colleagues conducted a retrospective cohort analysis including 111,353 Swedish patients aged ≥65 years who underwent hip fracture surgery between 2010 and 2018 [1]. Prof. Religa noted that 22% of the total study cohort had a dementia diagnosis. To examine the impact of dementia subtypes on mortality outcomes, 9 different subtypes were distinguished.
Not surprisingly, mortality rates after hip fracture surgery were higher in the group with dementia: mortality rates were 13% versus 6% (P<0.001) at 30 days post-fracture; 27% versus 12% (P<0.001) at 4 months; and 39% versus 20% (P<0.001) at 1 year. Prof. Religa added that higher American Society of Anesthesiologists (ASA) grades, poor baseline walking ability, and long-term care residency were also associated with increased mortality. Of the different dementia types, Parkinson’s disease dementia and Lewy body dementia were associated with the highest mortality, especially in the first 4 months after surgery.
- Religa D, et al. Mortality after hip fracture surgery in patients with dementia: large Swedish study of over 111 000 patients. OPR-067, EAN Congress 2025, 21-24 June 2025, Helsinki, Finland.
Medical writing support was provided by Michiel Tent.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Real-world data confirms effectiveness and safety of ofatumumab in MS Next Article
Lecanemab in AD: not a paradigm shift, but a small step forward »
« Real-world data confirms effectiveness and safety of ofatumumab in MS Next Article
Lecanemab in AD: not a paradigm shift, but a small step forward »
Table of Contents: EAN 2025
Featured articles
Lecanemab in AD: not a paradigm shift, but a small step forward
Why a good result of migraine treatment may not be good enough
Online First
Similar efficacy of anti-CGRP mAbs in short- and long-term migraine prevention
Occipital nerve stimulation is no more effective than placebo in cluster headache
Rituximab does not halt progression in non-active secondary progressive MS
Encouraging results for adaptive DBS for Parkinson’s disease
CAR T cell therapy shows promise in severe autoimmune neuropathies
GLP-1R agonists reduce migraine burden in obese patients
Is ChatGPT helpful in diagnosing polyneuropathies?
Lecanemab in AD: not a paradigm shift, but a small step forward
Dementia doubles mortality risk 1 year after hip fracture
Real-world data confirms effectiveness and safety of ofatumumab in MS
Virus-specific T cells show promise in treating PML
Comparable effectiveness and persistence of ocrelizumab, natalizumab
Why a good result of migraine treatment may not be good enough
Long-term benefits of cipa/mig in late-onset Pompe disease
Earlier add-on treatment in myasthenia gravis improves outcomes
Related Articles

December 20, 2022
Fingolimod in paediatric MS: results of up to 6 years
June 16, 2021
Predicting long-term prognosis in paediatric MS patients
August 22, 2022
Erenumab more than doubles plasma CGRP levels
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com